# Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease

Study · id `cardio:ct-nct04824911` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04824911](<https://clinicaltrials.gov/study/NCT04824911>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04824911

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 376 participants.

## Technical summary

Registry record NCT04824911. Non-randomized; no masking; primary purpose treatment. Start 2021-03-23 (actual); primary completion 2025-02-28 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 376 participants (enrolled count; ClinicalTrials.gov record NCT04824911, source copy `cardio:ctgov-nct04824911-2025-03-26`, retrieved 2026-10-26)
- Started: 2021-03-23 (actual) (ClinicalTrials.gov record NCT04824911, source copy `cardio:ctgov-nct04824911-2025-03-26`, retrieved 2026-10-26)
- Primary completion: 2025-02-28 (actual) (ClinicalTrials.gov record NCT04824911, source copy `cardio:ctgov-nct04824911-2025-03-26`, retrieved 2026-10-26)
- Completion: 2025-02-28 (actual) (ClinicalTrials.gov record NCT04824911, source copy `cardio:ctgov-nct04824911-2025-03-26`, retrieved 2026-10-26)
- Countries: Taiwan (ClinicalTrials.gov record NCT04824911, source copy `cardio:ctgov-nct04824911-2025-03-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04824911-2025-03-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Statin and Dual Antiplatelet Therapy to Prevent Early Neurological Deterioration in Branch Atheromatous Disease
- Acronym: SATBRAD
- Condition: Acute Stroke
- Condition: Dual Antiplatelet Therapy
- Condition: Statin
- Intervention (Drug): Clopidogrel
- Intervention (Drug): Aspirin
- Intervention (Drug): Atorvastatin
- Intervention (Drug): Rosuvastatin
- Lead sponsor: Chang Gung Memorial Hospital
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry intervention name matches this record: Clopidogrel (`cardio:clopidogrel`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry intervention name matches this record: Rosuvastatin (`cardio:rosuvastatin`)
- Registry lists this organization as the lead sponsor: Chang Gung Memorial Hospital (`cardio:org-chang-gung-memorial-hospital`)

## Provenance

Content hash: ac9d0a066f20870338a3844c50156ebb3414ada8352d136de5540ed2beea8284
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
